1 Department of Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China
2 The Chongqing Key Laboratory of Translation Medicine in Major Metabolic Diseases, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China
3 Department of Critical Care Medicine, People's Hospital of Fengjie, 404600 Chongqing, China
4 Department of Critical Care Medicine, Dazu Hospital of Chongqing Medical University, 402360 Chongqing, China
†These authors contributed equally.
Abstract
Acute lung injury (ALI) significantly impacts the survival rates in intensive care units (ICU). Releasing a lot of pro-inflammatory mediators during the progression of the disease is a core feature of ALI, which may lead to uncontrolled inflammation and further damages the tissues and organs of patients. This study explores the potential therapeutic mechanisms of Dexmedetomidine (Dex) in ALI.
In present study, cecal ligation puncture (CLP)-established ALI model mice and lipopolysaccharide (LPS)-stimulated RAW264.7 cell line were established to discover the influence of Dex. The evaluation of lung injury in vivo using histopathology, TUNEL assay, and analysis of inflammatory factors in bronchoalveolar lavage fluid (BALF) and serum. The receptor for advanced glycation end products (RAGE)/Caspase-11-dependent pyroptosis-related proteins and macrophage polarization markers were analyzed using western blot, immunofluorescence, and flow cytometry. Finally, the mechanism of Dex in macrophages was further verified in vitro.
In vivo, Dex alleviated lung injury and decreased TUNEL-positive cell expression in CLP group. Dex decreased tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6 and IL-17A levels in BALF and serum, while increasing IL-10 expression. Dex treatment decreased the protein levels of RAGE, caspase-11, IL-1β and Gasdermin-D (GSDMD) in both in cells and in mice. Dex also down-regulated the synthesis of inducible nitric oxide synthase (iNOS) of classical activation phenotype (M1) markers, and up-regulated the synthesis of CD206 and Arg-1 of alternate activation phenotype (M2) markers.
Dex treatment can inhibit inflammation and reduce lung injury caused by CLP. It could be associated with mediating M1 and M2 polarization and suppressing RAGE/Caspase-11-depended pyroptosis.
Keywords
- acute lung injury
- dexmedetomidine
- macrophage
- pyroptosis
Acute lung injury (ALI) and the syndrome after progression, acute respiratory distress syndrome (ARDS), are progressive diseases characterized by hypoxemia unresponsive to oxygen therapy, bilateral pulmonary infiltration, and increased lung consolidations [1]. The immune mechanisms underlying ALI remain incompletely understood. One of the suggested mechanisms by which ALI develops is an excessive and uncontrolled inflammatory state [2], which is closely linked to high morbidity and mortality [3, 4]. Despite increasing knowledge of ALI/ARDS pathogenesis, there are still no effective treatment strategies. Hence, finding alternative treatments for ALI/ARDS is an urgent medical need. Recent study has indicated that although the disease is highly heterogeneous and clinically complex, it may be possible to find personalized pharmacologic therapies to inhibit inflammation and improve this disorder [5].
Dexmedetomidine (Dex) is a short-acting, highly selective
In the initial progression of ALI, several pro-inflammatory cytokines and mediators are released, which may lead to uncontrolled inflammation and further damage to the tissues and organs of patients [10]. Dysfunction of immune regulation secondary to excessive inflammation is a key event in exacerbating ALI [11]. Therefore, inhibiting early uncontrolled inflammation, and improving immune regulation, may offer a new treatment method for ALI [12]. Macrophages are essential in regulating inflammation within the innate immune system. There are two types of polarization processes they undergo depending on how they respond to the internal environmental challenge, classical activation phenotype (M1) and alternate activation phenotype (M2) [13]. Increasingly, articles have reviewed the role of these two subtypes of macrophage in immune responses, and it seems possible that their appearance can influence the fate and development of diseases [14, 15]. M1 has been shown to exacerbate lung damage, whereas M2 promotes lung repair [16]. Macrophage subtypes and polarization are closely linked to ALI prognosis.
Pyroptosis, a type of programmed necrosis in the innate immune response, disrupts pathogen replication sites and kills intracellular bacteria via pore-induced intracellular traps [17, 18]. While beneficial, pyroptosis can cause uncontrolled inflammation if over-activated. Previous studies have shown that pyroptosis exacerbates the development of ALI [19, 20].
In terms of whether Dex protects against ALI/ARDS, and the possible underlying molecular mechanisms by which this could occur, have not yet been investigated. This study aims to the protective potential and mechanism of Dex in ALI Mice and macrophages.
Male C57BL/6 mice of this study, aged 6–8 weeks, weigh 18–22 g, were obtained from Chongqing Medical University. The entire study involved 15 mice. Each mouse was completely randomized into groups using a random number table. Before the experiment, the mice were kept free to eat and drink in specific pathogen free facility for at least 7 days. The Institutional Animal Care and Use Committee of Chongqing Medical University approved the procedures for the care and use of the mice. The First Affiliated Hospital of Chongqing Medical University Animal Ethics Committee approved the experimental scheme (reference number 2020-850).
Before performing CLP surgery, we administered inhalation anesthesia to the mice. In short, 5% isoflurane is used to induce anesthesia, and 2% isoflurane is used to maintain anesthesia. The operation method of CLP refers to previous research [21]. The cecum was exposed. Following a 5.0 mm ligation from the tip, puncture the cecal stump with a 22-gauge needle and squeeze out a small amount of intestinal contents. Sham operation control mice exposed cecal stump without ligation and puncture. After 24 h, all mice were euthanized via excessive carbon dioxide inhalation, and whole-blood and lung were collected for further analysis. Following ligation, 200 µL of PBS was administered into the right lung through the trachea and subsequently removed after 10 seconds as bronchoalveolar lavage fluid (BALF). Repeat the operation twice for the next analysis.
Mice were divided randomly by random number table into three groups (n = 5): (1) control; (2) CLP; and (3) CLP+Dex. Dexmedetomidine (SML0956, Sigma-aldrich, Darmstadt, Germany) was administered intraperitoneally at 50 µg/kg, 30 minutes post-CLP. The control mice intraperitoneally injected with the same amount of PBS. The dose of Dex was determined in previous studies [22, 23].
Lung tissue was fixed in paraformaldehyde (4%) for 24 hours (4 °C) and then embedded in paraffin. Then the slices were fixed on glass slides and stained with H&E (G1120, Solarbio, Beijing, China) to evaluate tissue damage with a photon microscope (Leica, Wetzlar, Germany). The lung-injury score results were obtained according to previously study of Mikawa et al. [24]. Alveolar congestion, hemorrhage, neutrophil infiltration, and transparent membrane formation were measured. Pathological damage was assessed using a 4-point scale: 0 = no or very slight damage, 1 = mild, 2 = moderate, 3 = serious, and 4 = very serious.
Apoptosis was evaluated by TUNEL assay, following the methodology of a previous study [25]. Following the in situ cell apoptosis detection kit instructions (G001-1, Jiancheng Biotechnology, Nanjing, China), the lung sample was sealed, fixed, and sliced into 4-µm-thick sections. Proteinase K was used to digest the tissue for 15 minutes at 37 °C after the endogenous peroxidase was blocked. The terminal deoxynucleotidyl transferase was diluted in a reaction buffer and applied to sections at 37 °C for 2 hours, followed by three 2-minute washes. Slice with a dilution of anti-digoxin antibody incubation at 37 °C for 30 minutes. Apoptotic cells were measured by 3,3′-diaminobenzidine chromogenic after about 20 min. For statistical analysis, three images were captured, and TUNEL-labeled cells were measured as reported previously [26].
An earlier study reported on the collection of whole blood and the preparation
of serum [27]. Serum and BALF were analyzed with ELISA kits for interleukin
(IL)-6, IL-10, tumor necrosis factor-alpha (TNF-
Rehydration and dewaxing of lung paraffin slices were performed. Triethylenediamine tetraacetic acid (GC202001, Servicebio, Wuhan, China) was used to retrieve antigens. Then sections were incubated with 5% BSA. The sections were incubated with anti-rat caspase-11 (1:100, NB120-10454, NOVUS, Littleton, CO, USA) or anti-mouse receptor for advanced glycation end products (RAGE, 1:100, ab37647, Abcam, Cambridge, UK) for 12 hours at 4 °C. Slices were incubated in the dark (room temperature) using either a FITC-labeled green secondary antibody (1:200, GB22403, Servicebio, Wuhan, China) for RAGE or a Cy3-labeled red secondary antibody (1:200, Servicebio, GB21302) for caspase-11. DAPI was applied to detected the nuclei. The immunofluorescence methods for inducible nitric oxide synthase (iNOS) and CD206 in RAW264.7 cells followed previously published protocols, with the primary antibodies substituted by rabbit anti-mouse CD206 antibody (1:100, 24595, Cell Signaling Technology, Danvers, MA, USA) and rat anti-mouse iNOS monoclonal antibody (1:1000, 740025T, Thermo Fisher Scientific, Waltham, MA, USA). FITC-goat anti-rat IgG (1:100, SA00003-11, proteintech, Wuhan, China) was used for iNOS, and goat anti-rabbit IgG-Cy3 (1:100, SA00009-2, proteintech, Wuhan, China) was used for CD206. Finally, the images were collected by confocal microscope (VS200-BU-L, OLYMPUS, Tokyo, Japan).
Total and nuclear protein samples in lung tissue and RAW264.7 cells were
prepared using diluted RIPA Lysis Buffer and a nuclear extraction kit (P0013B,
Beyotime, Shanghai, China). The prepared samples were transferred to polyvinylidene fluoride (PVDF)
membrane after separation on sodium dodecyl sulfate - polyacrylamide gel
electrophoresis (SDS-PAGE, 10–12%). After being washed and blocked at room
temperature for 2 hours, the membranes were incubated with primary antibodies at
4 °C overnight: (RAGE, 1:100, ab37647, Abcam, Cambridge, UK), NF-
qRT-PCR experiments based on the description of the previous research
[28]. In short, total mRNA samples were prepared from the lung tissue
and RAW264.7 cells according to the RNAiso Plus reagent instructions. cDNA was
synthesized using a Takara Technology cDNA synthesis kit. qRT-PCR was conducted
using the TB Green™–Premix Ex Taq™ II reagent kit
(RR820A, Takara, Kyoto, Japan) on a Bio-Rad CFX96 system (CFX96, Bio-Rad, Hercules, CA, USA) to evaluate the
mRNA expression levels of RAGE, caspase-11, iNOS, Arg-1, IL-1
Under anesthesia, whole blood samples were collected 24 hours post-CLP procedure, and PBMCs were isolated using Ficoll Histopaque (17544602, Cytiva, Logan, UT, USA) through density gradient centrifugation.
RAW 264.7 macrophage cell lines were obtained from the Cell Bank of the Chinese Academy of Sciences, Shanghai, China. All cells were validated by STR profiling and tested negative for mycoplasma. After counting 105 cells, all were cultured in 90% high glucose DMEM with 10% heat-activated FBS (Gibco, Carlsbad, CA, USA) in a humidified environment at 5% CO2 and 37 °C. We began with 105 cells per group and cultured them until reaching 80% confluence in a six-well plate. Three groups were established: a control group, an lipopolysaccharide (LPS)-stimulated group (500 ng/mL), and an LPS+Dex group (10 µM). The dosage of LPS and Dex were determined in previous research [29, 30]. The cells were collected for analysis after 24 hours.
Blank controls of harvested PBMCs and RAW264.7 cells underwent the same procedure as the samples, excluding flow-cytometry antibody staining. We used the fluorescent antibody of anti-CD11b-PerCP/Cyanine5.5 (101228, BioLegend, San Diego, CA, USA) and anti-F4/80-FITC (BioLegend, 123108) to test the macrophages in PBMCs. Fluorescent antibody staining was performed on cultured RAW264.7 cells and isolated PBMCs to assess the proportions of macrophage phenotypes (M1 CD86+; M2 CD206+). CD86 and CD206 were stained with anti-CD86-PE (105008, BioLegend, San Diego, CA, USA) and anti-CD206-APC (BioLegend, 141708), respectively, following the manufacturer’s instructions. A minimum of 105 cells were collected and analyzed using flow cytometer (DxFLEX, Beckman Coulter, Brea, CA, USA) and FlowJo V10 (BD Biosciences, Franklin Lakes, NJ, USA).
Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad Software
Inc., San Diego, CA, USA) and SPSS 21.0 (IBM-SPSS Statistics, Chicago, IL, USA).
A p-value
The role of Dex in the CLP mice model was assessed by measuring lung damage
through histological examination after H&E staining. Compared with the control
group, the lung injury score in CLP group was significantly higher (p
Fig. 1.
Dex treats lung injury in CLP mice. (A)
H&E staining scores and representative pictures (Scale bar = 100 µm, 50
µm). (B) The TUNEL-positive cells in the lung (Scale bar = 100 µm, 50
µm). Five random fields (200
NF-
ALI involves pyroptosis, a form of programmed cell death. Recent study indicates
that the lethality of the CLP mice is primarily dependent on caspase-11
activation, with the mechanism involving coordinated activities of the RAGE and
caspase-11/Gasdermin-D (GSDMD) pathways [33]. To determine if Dex mitigates CLP-induced lung
injury by affecting expression of RAGE and caspase-11-dependent pyroptosis, we
assessed pyroptosis-related protein and mRNA levels in lung tissue. qRT-PCR
analysis revealed significantly elevated mRNA levels of Rage and caspase-11 in
the CLP group exhibited higher levels than control group, but this difference was
reduced with Dex treatment (Fig. 2A). Western blot analysis revealed that Dex
treatment reduced the protein levels of cleaved-caspase-11, cleaved-GSDMD, and
IL-1
Fig. 2.
Dex inhibits RAGE/caspase-11 expression in the lung of CLP mice.
(A) The lung mRNA levels of RAGE and caspase-11. (B) The RAGE protein levels in
lung detected by western blotting. (C) Western blot detected the level of
pyroptosis-related proteins. (D) Immunofluorescence assays of RAGE and caspase-11
(Scale bar = 50 µm, 20 µm). Use at least three independent experiment
to calculate the mean (SD). n = 5. *p
Given the importance of M1 and M2 polarization in ALI development, a study was
conducted to determine if Dex’s anti-inflammatory effects influence this
polarization. Flow cytometry’ results founded that Dex treatment reduced the
proportion of M1 (F4/80+CD86+) (p
Fig. 3.
Dex inhibited M1-type and promoted M2-type polarization
in CLP-induced mouse model. (A) PBMCs were isolation and stained with
F4/80-FITC/CD86-PE (M1) and F4/80-FITC/CD206-APC (M2), flow cytometry was used to
test macrophage subset expression levels. (B,C) The western blot and qRT-PCR was
used to test iNOS (M1) and Arg-1 (M2) expressed in the lung upon CLP-induced
mouse model. Use at least three independent experiment to calculate the mean
(SD). n = 5. ns, no significance, *p
In RAW264.7, qRT-PCR results demonstrated that the LPS+Dex group exhibited
significantly lower Inos mRNA levels compared to the LPS group
(p
Fig. 4.
Dex inhibited M1-and promoted M2-type polarization in
LPS-Induced RAW264.7. (A,B) The qRT-PCR and western blot was used to test iNOS
(M1) and Arg-1(M2) expressed in RAW264.7. (C) Flow cytometry was used to test
macrophage subset expression levels of CD86-PE and CD206-APC in RAW264.7. (D)
Immunofluorescence intensity of iNOS (green) and CD206 (red) in RAW264.7 (Scale
bar = 20 µm). Use at least three independent experiment to calculate the
mean (SD). n = 5. ns, no significance, *p
Macrophages play a major role in tissue homeostasis [34]. A recent study has
indicated that caspase-11-induced macrophage pyroptosis is critical for the
development of sepsis [35]. Over-activation of pyroptosis would lead to
uncontrolled inflammation, and may aggravate the severity of ALI. In our
in vitro experiments, immunofluorescence images showed that RAGE and
caspase-11 intensities in the LPS group were higher than in controls, but were
decreased in the LPS+Dex group (p
Fig. 5.
Dex suppressed RAGE expression and caspase-11-mediated
pyroptosis in RAW264.7. (A) The IL-1
ALI is characterized by air-blood barrier disruption, hypoxemia, pulmonary edema
and respiratory dysfunction [36]. Though advances in treatments for ALI have been
made in recent years, there is still a high mortality rate. Substantial evidence
suggests that it is significant that explosive and persistent inflammation in the
progression of ALI [37], therefore, a potentially new treatment strategy to
alleviate the progression of ALI could be based on regulating
immune-system-mediated inflammatory responses [38]. Dex is known as is a
short-acting, highly selective agonist of the
Dex treatment reduced lung injury severity. The CLP+Dex group also showed a
decrease in apoptosis of alveolar epithelial cells. Pro-inflammatory
cytokines in BALF and serum are vital clinical features and meaningful
indicators of ALI. Our study found that the expression levels of inflammation
cytokines in serum and BALF of the experimental mice were lower after Dex
treatment. The mechanism could be associated with inhibiting NF-
In recent years, research on immune regulatory inflammatory response to ALI has
focused the exploration for effective therapies for ALI. Study reported that
MSC-sEV has a therapeutic function on certain lung diseases, such as ALI,
bronchopulmonary dysplasia and pulmonary hypertension, by immunoregulation of
pulmonary macrophages [43]. Macrophages play a key role in the innate immune
response in body. After contact with the pathogen, macrophages are activated to
release various cytokines and other mediators [44]. In addition, macrophages are
an essential medium for connecting the innate and acquired immune system
responses. In the initial phase of ALI, M1 labeled with CD86 are stimulated by
LPS, and other bacterial products, and release a variety of chemokines and
cytokines. These cytokines promote neutrophil infiltration and activation,
promoting the development of ALI [45]. M2 showing CD206 release insulin growth
factor, platelet-derived growth factor, and TGF-
Research increasingly indicates a close relationship between ALI severity and
pyroptosis occurrence [20, 50, 51]. Pyroptosis is induced by canonical or
non-canonical caspase-related signaling pathways [52], not only resulting cell
death but also activating excessive inflammatory responses. RAGE has been found
to have a vital role in the pathogenesis of ALI/ARDS. A previous study showed
that RAGE as a vehicle is directly associated with LPS-induced pyroptosis [53].
In addition, AGE/RAGE signaling is essential in influencing the production and
expression of TNF-
Pyroptosis occurs when caspase-11 in macrophages is activated, and be for against intracellular bacteria and endotoxins [55]. Although the inflammatory response is crucial for the host to defend itself against invading microbes [56], overactivation of macrophages may lead to an inflammatory cascade effect, which results in tissue injury and multiple organ dysfunction [35]. Different subtypes of macrophage have been shown to be involved with tissues pyroptosis. Experimental results have indicated that LPS could regulate the transformation of the phenotype from the M2 to the M1 type, and then promote the pyroptosis of adipose tissue [57]. Those results are consistent with our study: Dex treatment elevated the proportion of M2-type macrophages and reduced pyroptosis of the lung. From those results, we concluded that M2-type macrophage polarization is associated with lung pyroptosis alleviation. Many researches have suggested that LPS promotes cell pyroptosis of RAW264.7 [58]; the cell model, RAW264.7 macrophages treated by LPS, is known as a canonical cell line model for inflammation research. Pyroptosis can be induced by numerous stimuli, however, and the mechanism still remains unknown. A research has stated that the transport of LPS into the cytosol is assisted by RAGE, which mediate caspase-11-dependent pyroptosis [53]. To identify whether Dex treatment could restrict macrophage pyroptosis, we used an LPS-stimulated RAW264.7 cell line model [59]. Our results provide evidence that Dex can inhibit inflammation and reduce lung injury caused by CLP. It could be associated with regulating M1 and M2 macrophage polarization and suppressing RAGE/Caspase-11-depended pyroptosis.
In summary, macrophage subtype imbalance and caspase-11 activation-induced pyroptosis played an essential role in ALI. Dex treatment could induce macrophages to undergo an M1-to-M2 switch and alleviate caspase-11-dependent macrophage pyroptosis to improve ALI/ARDS, reduce the inflammatory statement, and protect lung tissue. These findings could offer a novel therapeutic approach for ALI.
Dexmedetomidine treatment reduces lung damage in CLP mice and restrains the expression of proinflammatory cytokines. Dexmedetomidine may achieve its effects by promoting M2 macrophage polarization and suppressing caspase-11-dependent pyroptosis. These findings suggest that dexmedetomidine could act as an immune modulator to regulate macrophage polarization and provide protection against ALI.
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
YZ and SL made contributions to the conception or design of the work. YZ, KL, LW, GK, and KX participated in the work of data acquisition, analysis, and interpretation. YZ, KL, and KX drafted the manuscript. SL reviewed and revised Sthe manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.
This study was approved by the Animal Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (Ref. 2020-850).
Not applicable.
This work was Sponsored by Natural Science Foundation of Chongqing, China (CSTB2024NSCQ-MSX0956 to SH Lin) and Innovation Project for Doctoral Students at the First Affiliated Hospital of Chongqing Medical University (CYYY-BSYJSCXXM-202209 to YS Zhao).
The authors declare no conflict of interest.
References
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.





